Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
11
03
2022
revised:
14
04
2022
accepted:
14
04
2022
pubmed:
28
4
2022
medline:
6
7
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Dramatic differences in outcome between early- and late-stage high-grade serous ovarian cancer (HGSC) suggest perhaps distinct genetic origins due to differences in exposures to mutational processes. Evidence to support this hypothesis was recently reported by comparative analysis of copy-number signatures between early- and late-stage HGSCs. See related article by Cheng et al., p. 2911.
Identifiants
pubmed: 35476137
pii: 694785
doi: 10.1158/1078-0432.CCR-22-0336
pmc: PMC9306310
doi:
Types de publication
Editorial
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2730-2732Commentaires et corrections
Type : CommentOn
Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Nat Genet. 2018 Aug;50(8):1189-1195
pubmed: 30013179
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
Nature. 2021 Feb;590(7846):492-497
pubmed: 33505027
Cancers (Basel). 2021 Dec 30;14(1):
pubmed: 35008332
Clin Cancer Res. 2022 Jul 1;28(13):2911-2922
pubmed: 35398881
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Nature. 2019 Jun;570(7761):385-389
pubmed: 31142840